CredibleX | $55,000,000 | (Dec 18, 2024)
Retellio | $1,300,000 | (Dec 18, 2024)
Chargezoom | $11,500,000 | (Dec 18, 2024)
oncgnostics GmbH
Germany
- Jena, Thüringen
- 11/09/2023
- Unknown
- Undisclosed Amount
oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
- Industry Biotechnology Research
- Website https://www.oncgnostics.com/
- LinkedIn https://www.linkedin.com/company/oncgnostics/about/
Related People
Martina SchmitzFounder
Germany -
Jena, Thuringia
oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
First product is our CE IVD marked test "GynTect", a 2nd-line test for reliably detecting cervical cancer.
A short comic (german) explains what GynTect is doing.
On the Seedmatch-platform, there are a lot of insides on our company (german) and two nice videos about our company.
2016: https://www.seedmatch.de/startups/oncgnostics-2
2017: https://www.seedmatch.de/startups/oncgnostics
BILT Incorporated | $21,000,000 | (Dec 18, 2024)
Fluid Biomed Inc. | $27,000,000 | (Dec 18, 2024)
FastWave Medical | $19,000,000 | (Dec 18, 2024)
Prequel.dev | $3,300,000 | (Dec 18, 2024)
Mili | $2,000,000 | (Dec 18, 2024)
Stand | $30,000,000 | (Dec 18, 2024)
Anatomy Financial | $19,000,000 | (Dec 18, 2024)
pagent.ai | Undisclosed Amount | (Dec 18, 2024)
Slip Robotics | $28,000,000 | (Dec 18, 2024)
Twill | $1,400,000 | (Dec 18, 2024)